期刊文献+

细胞周期检测点激酶1/2基因与放疗敏感性关系 被引量:1

A study on relation of chk1/2 with apoptostic sensitivity to radiotherapy of Lela cells
暂未订购
导出
摘要 目的观察宫颈癌HeLa细胞chk1/2基因表达改变对X射线诱导凋亡的影响。方法以脂质体为载体将chk1/2正义链和反义链转染HeLa细胞,用Western blot检测HeLa细胞中chk1/2蛋白的表达,用流式细胞仪和TUNEL法检测X射线照射后细胞凋亡率。结果转染chk1/2反义寡核苷酸可明显抑制chk1/2蛋白表达(F=22.69,P<0.05),X射线作用下细胞凋亡率明显高于转染正义链组(F=23.65,P<0.05)。结论反义封闭chk1/2基因可增加HeLa细胞对X射线照射的凋亡敏感性。 Objective To investigate influence of alteration in enpression of checkpoint kinase1/2 (chk1/2)on induced X-ray apoptosis of cervical cancer cells HeLa. Methods The positive - sense and anti-sense strands of oligonucleotide were transfected into HeLa cells through vector liposome. The expression of chk1/2 was detected by using Western blot method. The apoptosis rate of HeLa cells after X-ray radiation was detected by flow cytometer and TUNEL method. Results Transfection with antisense oligonuleotide of chk1/2 inhibited expression of chk1/2 protein in the Lela cells ( F = 22.69, P 〈 0.05 ), and the apoptosis rate after X-ray radiation was significantly higher than that of the positive-sense oligonuleotide transfection group ( F = 23.65, P 〈 0. 05 ). Conclusion Antisense blocking of chk1/2 gene could increase apoptostic sensitivity of HeLa cells to X-ray radiation.
出处 《中国妇幼健康研究》 2008年第6期549-551,644,共4页 Chinese Journal of Woman and Child Health Research
基金 陕西省科技计划资助项目(2006K09-G11-3)
关键词 chk1基因 ehk2基因 反义核酸技术 宫颈癌 放射敏感性 chkl gene chk2 gene antisense nucleic acid technology cervical cancer radiosensitivity
  • 相关文献

参考文献5

二级参考文献45

  • 1苏应宽 刘新民.妇产科手术学[M].北京:人民卫生出版社,1992.103.
  • 2DeVitaVT Hellman Jr S Rosenberg SA 徐从高 张茂宏 杨兴秀 译.肿瘤学原理和实践:第5版[M].济南:山东科技出版社,2001.1499-1502,2961-2962.
  • 3Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW,Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
  • 4Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor. Clin Cancer Res 1996; 2: 791-7.
  • 5Bunch RT, Eastman A. 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S phase arrest in Chinese hamster ovary cells. Cell Growth Differ 1997; 8: 779-88.
  • 6Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS, Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA -dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J1999; 18: 1397-406.
  • 7Akinaga S, Gomi K, Morimoto M, Tomaoki T, Okabe M.Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991; 51: 4888-92.
  • 8Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA,Worland PJ. Differential inhibition of protein kinase C isozymes by, UCN-01, a staurosporine analogue. Mol Pharmacol 1994; 45: 1207-14.
  • 9Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01 a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32: 183-9.
  • 10Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chkl checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277: 1497- 501.

共引文献186

同被引文献19

  • 1朱克修,王佳,李玢,曹亚莉,韩晓兵.chk1反义寡核苷酸增加HeLa细胞顺铂作用下凋亡敏感性[J].第四军医大学学报,2007,28(19):1768-1770. 被引量:2
  • 2Kurta ML, Edwards RP, Moysich KB, et al, Prognosis and conditional disease-flee survival among patients with ovarian cancer [J]. Journal of clinical oncology, 2014, 32(36): 4102-4112.
  • 3Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future [J]. Cell death & disease, 2014, 5 (5): e1257.
  • 4Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells [J]. International journal of oncology, 2007, 31 (2): 277-283.
  • 5Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer [J]. Current drug targets, 2012, 13(13): 1649-1653.
  • 6Sakurikar N, Eastman A. Will targeting Chkl have a role in the future of cancer therapy? [J]. Journal of clinical oncology, 2015, 33 (9): 1075- 1077.
  • 7Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors [J]. Journal of clinical oncology, 2015, 33 (9): 1060-1066.
  • 8Zhang Y, Hunter T. Roles of Chkl in cell biology and cancer therapy [J]. International journal of cancer. Journal international du cancer, 2014, 134(5): 1013-1023.
  • 9Baranski Z, Booij TH, Cleton-Jansen AM, et al. Aven-mediated checkpoint kinase control regUlates proliferation and resistance to chemotherapy in conventional osteosarcoma [J]. The Journal of pathology, 2015, 236(3): 348-359.
  • 10Berlran E, Crosas-Molist E, Sancho P, et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells [J]. Hepatology, 2013, 58(6): 2032-2044.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部